Balchem Q1 Sales Rise 8.1% to $270.7M, EBITDA Up 12.1%
Balchem posted Q1 net sales of $270.7M (8.1% growth), earnings of $40.3M (+8.7%), adjusted EBITDA of $74.3M (+12.1%) and free cash flow of $33.8M. Human Nutrition sales rose 8.3% to $171.6M; Animal Nutrition sales rose 8.6% to $62.2M; Specialty Products sales rose 4.4% to $34.7M and earnings rose 24.5%.
1. Q1 Financial Results
Balchem generated net sales of $270.7 million in Q1 2026, marking an 8.1% increase over the prior year quarter. GAAP net earnings rose 8.7% to $40.3 million, adjusted EBITDA climbed 12.1% to $74.3 million, and free cash flow reached $33.8 million.
2. Segment Performance
The Human Nutrition and Health segment delivered $171.6 million in sales, up 8.3%, with earnings from operations increasing 5.4%. Animal Nutrition and Health sales grew 8.6% to $62.2 million, driving an 8.7% rise in segment operating income, while Specialty Products recorded $34.7 million in sales (up 4.4%) and a 24.5% jump in operating earnings.
3. Research and Sustainability Initiatives
New fMRI-based clinical research using VitaCholine® indicates enhanced brain network efficiency in post-menopausal women, suggesting cognitive health benefits. Balchem also published its 2025 Sustainability Report, outlining progress on environmental stewardship, global health solutions and strategic growth initiatives.